Development of disease-modifying treatment of schizophrenia

Handbook of Experimental Pharmacology

Volumn 213, Issue , 2012, Pages 419-442

  Bespalov, Anton ^a   Klein, Corinna ^a   Behl, Berthold ^a   Gross, Gerhard ^a,b   Schoemaker, Hans ^a  

^a ABBOTT GMBH AND CO KG   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Cognitive behavioral therapy; Demyelination; Drug environment interaction; Epigenetics; Extracellular matrix; Neurodegeneration; Neurogenesis; Neuroinflammation; Plasticity

Indexed keywords

BENZODIAZEPINE DERIVATIVE; BITOPERTIN; CLOZAPINE; FLUOXETINE; HISTONE DEACETYLASE 2; KYNURENINE AMINOTRANSFERASE; MYELIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; PREGNENOLONE; RISPERIDONE; SULPIRIDE; TPA 023; UNCLASSIFIED DRUG; VALPROIC ACID;

ACUTE DISEASE; ARTICLE; CHRONIC DISEASE; CLINICAL EFFECTIVENESS; COGNITIVE THERAPY; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE COURSE; DISEASE EXACERBATION; DISEASE MARKER; DISEASE SEVERITY; ENVIRONMENTAL FACTOR; EPIGENETICS; EXTRACELLULAR MATRIX; GABAERGIC SYSTEM; GABAERGIC TRANSMISSION; HUMAN; INTERNEURON; MYELIN DEFICIENCY; NEGATIVE SYNDROME; NERVE CELL MEMBRANE POTENTIAL; NERVE CELL NETWORK; NERVE CELL PLASTICITY; NERVE DEGENERATION; NERVOUS SYSTEM DEVELOPMENT; NERVOUS SYSTEM INFLAMMATION; NEUROANATOMY; NEUROPROTECTION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOSIS; RISK FACTOR; RISK MANAGEMENT; SCHIZOPHRENIA; SYMPTOM; SYNAPSE; ANIMAL; GENETIC EPIGENESIS; PHYSIOLOGY; REVIEW;

ANIMALS; ANTIPSYCHOTIC AGENTS; EPIGENESIS, GENETIC; HUMANS; NEUROGENESIS; NEURONAL PLASTICITY; SCHIZOPHRENIA; SYNAPSES;

EID: 84868306034     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-642-25758-2_14     Document Type: Article

References (87)

1. Adcock RA, Dale C, Fisher M, Aldebot S, Genevsky A, Simpson GV, Nagarajan S, Vinogradov S (2009) When top-down meets bottom-up: auditory training enhances verbal memory in schizophrenia. Schizophr Bull 35:1132-1141
2. Akbarian S (2010) Epigenetics of schizophrenia. Curr Top Behav Neurosci 4:611-628
3. Akhondzadeh S, Tabatabaee M, Amini H, Ahmadi Abhari SA, Abbasi SH, Behnam B (2007) Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr Res 90:179-185 (Pubitemid 46177578)
4. Aloy E, Weinmann O, Pot C, Kasper H, Dodd D, Rülicke T, Rossi F, Schwab M (2006) Synaptic destabilization by neuronal Nogo-A. Brain Cell Biol 35:137-157 (Pubitemid 47630633)
5. Arnsten AFT (1998) Catecholamine modulation of prefrontal cortical cognitive function. Trends Cogn Sci 2:436-447 (Pubitemid 28518356)
6. Balu DT, Basu AC, Corradi JP, Cacace AM, Coyle JT (2012) The NMDA receptor co-agonists, d-serine and glycine, regulate neuronal dendritic architecture in the somatosensory cortex. Neurobiol Dis 45(2):671-682
7. Bayer TA, Falkai P, Maier W (2011) Genetic and non-genetic vulnerability factors in schizophrenia: the basis of the "two hit hypothesis". J Psychiatr Res 33:543-548
8. Becker A, Grecksch G (2004) Ketamine-induced changes in rat behaviour: a possible animal model of schizophrenia. Test of predictive validity. Prog Neuropsychopharmacol Biol Psychiatry 28:1267-1277 (Pubitemid 39592924)
9. Behrens MM, Sejnowski TJ (2009) Does schizophrenia arise from oxidative dysregulation of parvalbumin-interneurons in the developing cortex? Neuropharmacology 57:193-200
10. Benes FM, Paskevich PA, Davidson J, Domesick VB (1985) Synaptic rearrangements in medial prefrontal cortex of haloperidol-treated rats. Brain Res 348:15-20 (Pubitemid 16235736)
11. Berretta S (2012) Extracellular matrix abnormalities in schizophrenia. Neuropharmacology 62:1584-1597. doi:10.1016/j.neuropharm.2011.08.010:
12. Buchanan RW, Keefe RSE, Lieberman JA, Barch DM, Csernansky JG, Goff DC, Gold JM, Green MF, Jarskog LF, Javitt DC, Kimhy D, Kraus MS, McEvoy JP, Mesholam-Gately RI, Seidman LJ, Ball MP, McMahon RP, Kern RS, Robinson J, Marder SR (2011) A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biol Psychiatry 69:442-449
13. Budel S, Padukkavidana T, Liu BP, Feng Z, Hu F, Johnson S, Lauren J, Park JH, McGee AW, Liao J, Stillman A, Kim JE, Yang BZ, Sodi S, Gelernter J, Zhao H, Hisama F, Arnsten AFT, Strittmatter SM (2008) Genetic variants of Nogo-66 receptor with possible association to schizophrenia block myelin inhibition of axon growth. J Neurosci 28:13161-13172
14. Callicott JH, Mattay VS, Verchinski BA, Marenco S, Egan MF, Weinberger DR (2003) Complexity of prefrontal cortical dysfunction in schizophrenia: more than up or down. Am J Psychiatry 160:2209-2215 (Pubitemid 39619615)
15. Cameron HA, Dayer AG (2008) New interneurons in the adult neocortex: small, sparse, but significant? Biol Psychiatry 63:650-655
16. Campo CG, Sinagra M, Dl V, Manzoni OJ, Chavis P (2009) Reelin secreted by GABAergic neurons regulates glutamate receptor homeostasis. PLoS One 4:e5505
17. Castner SA, Arriza JL, Roberts JC, Mrzljak L, Christian EP, Williams GV (2010) Reversal of ketamine-induced working memory impairments by the GABAA[alpha]2/3 agonist TPA023. Biol Psychiatry 67:998-1001
18. Chen Y, Hancock ML, Role LW, Talmage DA (2010) Intramembranous valine linked to schizophrenia is required for neuregulin 1 regulation of the morphological development of cortical neurons. J Neurosci 30:9199-9208
19. Cornblatt BA, Lencz T, Smith CW, Olsen R, Auther AM, Nakayama E, Lesser ML, Tai JY, Shah MR, Foley CA, Kane JM, Correll CU (2007) Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. J Clin Psychiatry 68:546-557 (Pubitemid 46663037)
20. Croquelois A, Bronchti G, Welker E (2005) Cortical origin of functional recovery in the somato-sensory cortex of the adult mouse after thalamic lesion. Eur J Neurosci 21:1798-1806 (Pubitemid 40685860)
21. Delini-Stula A, Berdah-Tordjman D (1996) Antipsychotic effects of bretazenil, a partial benzodi-azepine agonist in acute schizophrenia - a study group report. J Psychiatr Res 30:239-250 (Pubitemid 26340786)
22. Dong E, Guidotti A, Grayson DR, Costa E (2007) Histone hyperacetylation induces demethylation of reelin and 67-kDa glutamic acid decarboxylase promoters. Proc Natl Acad Sci 104:4676-4681 (Pubitemid 47186284)
23. Elsworth JD, Morrow BA, Hajszan T, Leranth C, Roth RH (2011) Phencyclidine-induced loss of asymmetric spine synapses in rodent prefrontal cortex is reversed by acute and chronic treatment with olanzapine. Neuropsychopharmacology 36:2054-2061
24. Fischer A, Sananbenesi F, Mungenast A, Tsai LH (2010) Targeting the correct HDAC(s) to treat cognitive disorders. Trends Pharmacol Sci 31:605-617
25. Fischer A, Sananbenesi F, Wang X, Dobbin M, Tsai LH (2007) Recovery of learning and memory is associated with chromatin remodelling. Nature 447:178-182 (Pubitemid 46763080)
26. Fisher M, Holland C, Merzenich MM, Vinogradov S (2009) Using neuroplasticity-based auditory training to improve verbal memory in schizophrenia. Am J Psychiatry 166:805-811
27. Fisher M, Holland C, Subramaniam K, Vinogradov S (2010) Neuroplasticity-based cognitive training in schizophrenia: an interim report on the effects 6 months later. Schizophr Bull 36:869-879
28. Foeller E, Celikel T, Feldman DE (2005) Inhibitory sharpening of receptive fields contributes to whisker map plasticity in rat somatosensory cortex. J Neurophysiol 94:4387-4400 (Pubitemid 41691793)
29. Fu M, Zuo Y (2011) Experience-dependent structural plasticity in the cortex. Trends Neurosci 34:177-187
30. Glick ID, Bosch J, Casey DE (2009) A double-blind randomized trial of mood stabilizer augmentation using lamotrigine and valproate for patients with schizophrenia who are stabilized and partially responsive. J Clin Psychopharmacol 29:267-271
31. Gogolla N, Caroni P, Luthi A, Herry C (2009) Perineuronal nets orotect fear memories from erasure. Science 325:1258-1261
32. Gozzi A, Herdon H, Schwarz A, Bertani S, Crestan V, Turrini G, Bifone A (2008) Pharmacological stimulation of NMDA receptors via co-agonist site suppresses fMRI response to phencyclidine in the rat. Psychopharmacology (Berl) 201:273-284
33. Guidotti A, Dong E, Kundakovic M, Satta R, Grayson DR, Costa E (2009) Characterization of the action of antipsychotic subtypes on valproate-induced chromatin remodeling. Trends Pharmacol Sci 30:55-60
34. Gundelfinger ED, Frischknecht R, Choquet D, Heine M (2010) Converting juvenile into adult plasticity: a role for the brain's extracellular matrix. Eur J Neurosci 31:2156-2165
35. Haas DA, Harper DG (1992) Ketamine: a review of its pharmacologic properties and use in ambulatory anesthesia. Anesth Prog 39:61-68 (Pubitemid 23173642)
36. Hensch TK (2005) Critical period plasticity in local cortical circuits. Nat Rev Neurosci 6:877-888 (Pubitemid 41568729)
37. Holtmaat A, Wilbrecht L, Knott GW, Welker E, Svoboda K (2006) Experience-dependent and cell-type-specific spine growth in the neocortex. Nature 441:979-983 (Pubitemid 43980351)
38. Insel TR (2010) Rethinking schizophrenia. Nature 468:187-193
39. Iwai Y, Fagiolini M, Obata K, Hensch TK (2003) Rapid critical period induction by tonic inhibition in visual cortex. J Neurosci 23:6695-6702 (Pubitemid 36951197)
40. Jaaro-Peled H (2009) Gene models of schizophrenia: DISC1 mouse models. In: Sawa A, Sawa A (eds) Progress in brain research genetic models of schizophrenia. Elsevier, Amsterdam, pp 75-86
41. Jawerka M, Colak D, Dimou L, Spiller C, Lagger S, Montgomery RL, Olson EN, Wurst W, Gottlicher M, Gotz M (2010) The specific role of histone deacetylase 2 in adult neurogenesis. Neuron Glia Biol 6:93-107
42. Kato TA, Monji A, Mizoguchi Y, Hashioka S, Horikawa H, Seki Y, Kasai M, Utsumi H, Kanba S (2011) Anti-inflammatory properties of antipsychotics via microglia modulations; are antipsychotics a 'fire extinguisher' in the brain of schizophrenia? Mini Rev Med Chem 11(7):565-574
43. Keefe RSE, Vinogradov S, Medalia A, Silverstein SM, Bell MD, Dickinson D, Ventura J, Marder SR, Stroup TS (2011) Report from the working group conference on multisite trial design for cognitive remediation in schizophrenia. Schizophr Bull 37:1057-1065
44. Kelly DL, Conley RR, Feldman S, Yu Y, McMahon RP, Richardson CM (2006) Adjunct divalproex or lithium to clozapine in treatment-resistant schizophrenia. Psychiatr Q 77:81-95 (Pubitemid 43060798)
45. Kippin TE, Kapur S, van der Kooy D (2005) Dopamine specifically inhibits forebrain neural stem cell proliferation, suggesting a novel effect of antipsychotic drugs. J Neurosci 25:5815-5823 (Pubitemid 40847894)
46. Knott GW, Quairiaux C, Genoud C, Welker E (2002) Formation of dendritic spines with GABAergic synapses induced by whisker stimulation in adult mice. Neuron 34:265-273 (Pubitemid 34442569)
47. Kolluri N, Sun Z, Sampson AR, Lewis DA (2005) Lamina-specific reductions in dendritic spine density in the prefrontal cortex of subjects with schizophrenia. Am J Psychiatry 162:1200-1202 (Pubitemid 40770705)
48. Laan W, Grobbee DE, Selten JP, Heijnen CJ, Kahn RS, Burger H (2010) Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 71:520-527
49. Lee H, Raiker SJ, Venkatesh K, Geary R, Robak LA, Zhang Y, Yeh HH, Shrager P, Giger RJ (2008) Synaptic function for the Nogo-66 receptor NgR1: regulation of dendritic spine morphology and activity-dependent synaptic strength. J Neurosci 28:2753-2765 (Pubitemid 351398865)
50. Lewis DA, Volk DW, Hashimoto T (2004) Selective alterations in prefrontal cortical GABA neurotransmission in schizophrenia: a novel target for the treatment of working memory dysfunction. Psychopharmacology (Berl) 174:143-150 (Pubitemid 38925099)
51. Lewis DA, Cho RY, Carter CS, Eklund K, Forster S, Kelly MA, Montrose D (2008) Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia. Am J Psychiatry 165:1585-1593
52. Lewis DA, Moghaddam B (2006) Cognitive dysfunction in schizophrenia: convergence of {gamma}-aminobutyric acid and glutamate alterations. Arch Neurol 63:1372-1376 (Pubitemid 44547546)
53. Li Y, Kolb B, Robinson TE (2003) The location of persistent amphetamine-induced changes in the density of dendritic spines on medium spiny neurons in the nucleus accumbens and caudate-putamen. Neuropsychopharmacology 28:1082-1085
54. Loukavenko EA, Ottley MC, Moran JP, Wolff M, Dalrymple-Alford JC (2007) Towards therapy to relieve memory impairment after anterior thalamic lesions: improved spatial working memory after immediate and delayed postoperative enrichment. Eur J Neurosci 26:3267-3276 (Pubitemid 350135160)
55. Maloku E, Kadriu B, Zhubi A, Dong E, Pibiri F, Satta R, Guidotti A (2011) Selective [alpha]4 [beta]2 nicotinic acetylcholine receptor agonists target epigenetic mechanisms in cortical GABAergic neurons. Neuropsychopharmacology 36:1366-1374
56. Marx CE, Bradford DW, Hamer RM, Naylor JC, Allen TB, Lieberman JA, Strauss JL, Kilts JD (2011) Pregnenolone as a novel therapeutic candidate in schizophrenia: emerging preclinical and clinical evidence. Neuroscience 191:78-90
57. McGee AW, Yang Y, Fischer QS, Daw NW, Strittmatter SM (2005) Experience-driven plasticity of visual cortex limited by myelin and Nogo receptor. Science 309:2222-2226 (Pubitemid 41396073)
58. McGurk SR, Twamley EW, Sitzer DI, McHugo GJ, Mueser KT (2007) A meta-analysis of cognitive remediation in schizophrenia. Am J Psychiatry 164:1791-1802 (Pubitemid 351739231)
59. Meyer U, Schwarz MJ, Müller N (2011) Inflammatory processes in schizophrenia: a promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond. Pharmacol Ther 132:96-110
60. Mouret A, Gheusi G, Gabellec MM, de Chaumont F, Olivo-Marin JC, Lledo PM (2008) Learning and survival of newly generated neurons: when time matters. J Neurosci 28:11511-11516
61. Müller N, Riedel M, Scheppach C, Brandstatter B, Sokullu S, Krampe K, Ulmschneider M, Engel RR, Möller HJ, Schwarz MJ (2002) Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry 159:1029-1034 (Pubitemid 34586950)
62. Namba T, Gl M, Song H, Waga C, Enomoto A, Kaibuchi K, Kohsaka S, Uchino S (2011) NMDA receptor regulates migration of newly generated neurons in the adult hippocampus via Disrupted-In-Schizophrenia 1 (DISC1). J Neurochem 118:34-44
63. Newton SS, Duman RS (2007) Neurogenic actions of atypical antipsychotic drugs and therapeutic implications. CNS Drugs 21:715-725 (Pubitemid 47294718)
64. Olney JW, Labruyere J, Wang G, Wozniak DF, Price MT, Sesma MA (1991) NMDA antagonist neurotoxicity: mechanism and prevention. Science 254:1515-1518 (Pubitemid 21917493)
65. Pantazopoulos H, Woo TU, Lim MP, Lange N, Berretta S (2010) Extracellular matrix-glial abnormalities in the amygdala and entorhinal cortex of subjects diagnosed with schizophrenia. Arch Gen Psychiatry 67:155-166
66. Papadopoulos CM, Tsai SY, Cheatwood JL, Bollnow MR, Kolb BE, Schwab ME, Kartje GL (2006) Dendritic plasticity in the adult rat following middle cerebral artery occlusion and Nogo-a neutralization. Cereb Cortex 16:529-536
67. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, Avedisova AS, Bardenstein LM, Gurovich IY, Morozova MA, Mosolov SN, Neznanov NG, Reznik AM, Smulevich AB, Tochilov VA, Johnson BG, Monn JA, Schoepp DD (2007) Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 13:1102-1107 (Pubitemid 47517511)
68. Pato CN, Wolkowitz OM, Rapaport M, Schulz SC, Pickar D (1989) Benzodiazepine augmentation of neuroleptic treatment in patients with schizophrenia. Psychopharmacol Bull 25:263-266 (Pubitemid 19273160)
69. Pavlov I, Rauvala H, Taira T (2006) Enhanced hippocampal GABAergic inhibition in mice overexpressing heparin-binding growth-associated molecule. Neuroscience 139:505-511
70. Pinna G, Costa E, Guidotti A (2009) SSRIs act as selective brain steroidogenic stimulants (SBSSs) at low doses that are inactive on 5-HT reuptake. Curr Opin Pharmacol 9:24-30
71. Pizzorusso T, Medini P, Berardi N, Chierzi S, Fawcett JW, Maffei L (2002) Reactivation of ocular dominance plasticity in the adult visual cortex. Science 298:1248-1251 (Pubitemid 35285495)
72. Powell SB, Risbrough VB, Geyer MA (2003) Potential use of animal models to examine antipsy-chotic prophylaxis for schizophrenia. Clin Neurosci Res 3:289-296 (Pubitemid 37461294)
73. Rao SG, Williams GV, Goldman-Rakic PS (2000) Destruction and creation of spatial tuning by disinhibition: GABA(A) blockade of prefrontal cortical neurons engaged by working memory. J Neurosci 20:485-494 (Pubitemid 30220534)
74. Reif A, Fritzen S, Finger M, Strobel A, Lauer M, Schmitt A, Lesch KP (2006) Neural stem cell proliferation is decreased in schizophrenia, but not in depression. Mol Psychiatry 11:514-522
75. Seeley WW, Turetsky N, Reus VI, Wolkowitz OM (2002) Benzodiazepines in schizophrenia: prefrontal cortex atrophy predicts clinical response to alprazolam augmentation. World J Biol Psychiatry 3:221-224
76. Selemon LD, Begovic A, Goldman-Rakic PS, Castner SA (2006) Amphetamine sensitization alters dendritic morphology in prefrontal cortical pyramidal neurons in the non-human primate. Neuropsychopharmacology 32:919-931 (Pubitemid 46426180)
77. Takahashi N, Sakurai T, Davis KL, Buxbaum JD (2011) Linking oligodendrocyte and myelin dysfunction to neurocircuitry abnormalities in schizophrenia. Prog Neurobiol 93:13-24
78. Takeuchi H, Sekiguchi A, Taki Y, Yokoyama S, Yomogida Y, Komuro N, Yamanouchi T, Suzuki S, Kawashima R (2010) Training of working memory impacts structural connectivity. J Neurosci 30:3297-3303
79. Tregellas JR, Tanabe J, Rojas DC, Shatti S, Olincy A, Johnson L, Martin LF, Soti F, Kem WR, Leonard S, Freedman R (2011) Effects of an alpha 7-nicotinic agonist on default network activity in schizophrenia. Biol Psychiatry 69:7-11
80. Volz A, Khorsand V, Gillies D, Leucht S (2007) Benzodiazepines for schizophrenia. Cochrane Database Syst Rev Issue 1. Art. No.: CD006391
81. Waddell J, Shors TJ (2008) Neurogenesis, learning and associative strength. Eur J Neurosci 27:3020-3028 (Pubitemid 351832208)
82. Wang HD, Deutch AY (2008) Dopamine depletion of the prefrontal cortex induces dendritic spine loss: reversal by atypical antipsychotic drug treatment. Neuropsychopharmacology 33:1276-1286 (Pubitemid 351521724)
83. Wang Y, Fujita I, Murayama Y (2000) Neuronal mechanisms of selectivity for object features revealed by blocking inhibition in inferotemporal cortex. Nat Neurosci 3:807-813 (Pubitemid 30485706)
84. Whitford TJ, Kubicki M, Schneiderman JS, O'Donnell LJ, King R, Alvarado JL, Khan U, Markant D, Nestor PG, Niznikiewicz M, McCarley RW, Westin CF, Shenton ME (2010) Corpus callosum abnormalities and their association with psychotic symptoms in patients with schizophrenia. Biol Psychiatry 68:70-77
85. Wonodi I, Schwarcz R (2010) Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in schizophrenia. Schizophr Bull 36:211-218
86. Woods SW, Addington J, Cadenhead KS, Cannon TD, Cornblatt BA, Heinssen R, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, McGlashan TH (2009) Validity of the prodromal risk syndrome for first psychosis: findings from the North American Prodrome Longitudinal Study. Schizophr Bull 35:894-908
87. Xu H, Yang HJ, Rose GM, Li XM (2011) Recovery of behavioral changes and compromised white matter in C57BL/6 mice exposed to cuprizone: effects of antipsychotic drugs. Front Behav Neurosci 5:31